Humicade™: New anti-TNF? therapy for Crohn’s disease

• steroid withdrawal 273 patients 8 mths + follow-up
• active disease 397 patients 7 mths + follow-up

• US BLA submission 02

• Ph III pivotal studies

Total database

1000 patients

• Ph II studies

• paediatric Crohn’s
• patients hypersensitive to infliximab

• Recruitment completed

Previous slide

Next slide

Back to first slide

View graphic version